A Two-part, Single Center, Open-label Study to Investigate the Pharmacokinetics, Metabolic Disposition, Mass Balance and Absolute Bioavailability of BAY 2927088 in Healthy Male Participants
Latest Information Update: 11 Jul 2024
At a glance
- Drugs BAY 2927088 (Primary) ; BAY 2927088 (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Bayer
Most Recent Events
- 08 Apr 2024 Status changed from active, no longer recruiting to completed.
- 12 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2024 New trial record